Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + fluorouracil + leucovorin + oxaliplatin
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
This therapeutic regimen involves the use of Isolated Hepatic Perfusion (IHP) to deliver high-dose melphalan directly to the liver, followed by systemic administration of the FOLFOX4 regimen (fluorouracil, leucovorin, and oxaliplatin). Developed and studied by the National Cancer Institute (NCI), this approach is designed for patients with unresectable metastatic colorectal cancer confined primarily to the liver. IHP allows for the delivery of chemotherapy concentrations to the liver that would be toxic if given systemically, by surgically isolating the hepatic circulation from the rest of the body's blood supply. Melphalan acts as a DNA alkylating agent, while the FOLFOX4 components provide complementary systemic control of micrometastatic disease.
- Other names
- IHP-melphalan + FOLFOX4isolated hepatic perfusion with melphalan and FOLFOX4isolated perfusion-National Cancer Institute (NCI)-colorectal cancer
02
Targets
DNANucleotide synth (Nucleotide synthesis enzymes)
Beyond the preview
Go deeper on melphalan + fluorouracil + leucovorin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + fluorouracil + leucovorin + oxaliplatin.